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Abstract
Introduction: HIV-infected prisoners lose viral suppression within the 12 weeks after release to the community. This
prospective study evaluates the use of buprenorphine/naloxone (BPN/NLX) as a method to reduce relapse to opioid use and
sustain viral suppression among released HIV-infected prisoners meeting criteria for opioid dependence (OD).
Methods: From 2005–2010, 94 subjects meeting DSM-IV criteria for OD were recruited from a 24-week prospective trial of
directly administered antiretroviral therapy (DAART) for released HIV-infected prisoners; 50 (53%) selected BPN/NLX and
were eligible to receive it for 6 months; the remaining 44 (47%) selected no BPN/NLX therapy. Maximum viral suppression
(MVS), defined as HIV-1 RNA,50 copies/mL, was compared for the BPN/NLX and non-BPN/NLX (N=44) groups.
Results: The two groups were similar, except the BPN/NLX group was significantly more likely to be Hispanic (56.0% v
20.4%), from Hartford (74.4% v 47.7%) and have higher mean global health quality of life indicator scores (54.18 v 51.40).
MVS after 24 weeks of being released was statistically correlated with 24-week retention on BPN/NLX [AOR=5.37 (1.15,
25.1)], having MVS at the time of prison-release [AOR=10.5 (3.21, 34.1)] and negatively with being Black [AOR=0.13 (0.03,
0.68)]. Receiving DAART or methadone did not correlate with MVS.
Conclusions: In recognition that OD is a chronic relapsing disease, strategies that initiate and retain HIV-infected prisoners
with OD on BPN/NLX is an important strategy for improving HIV treatment outcomes as a community transition strategy.
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Introduction
Combination antiretroviral therapy (cART) has markedly
reduced morbidity and mortality from HIV disease. [1] Despite
more simplified regimens and a myriad of interventions to improve
HIV detection and treatment, fewer than 20% of all people with
HIV/AIDS (PLWHA) in the United States (U.S.) achieve viral
suppression (VS). [2] Maximal viral suppression (MVS), defined as
achieving a HIV-1 RNA level below 50 copies/mL, is associated
with improved HIV treatment outcomes compared to those who
suppress HIV-1 RNA levels to less than 400 copies/mL, but who
do not achieve MVS. [3] Sustained VS, using effective cART as
prevention, has recently been demonstrated to reduce HIV
transmission by 96% among HIV serodiscordant heterosexual
couples. [4].
Individuals with HIV disease transitioning to the community
from the criminal justice system (CJS) are a particularly vulnerable
population where effective interventions are urgently needed. [5]
Within U.S. prisons, HIV and AIDS is three and four times
greater, respectively, than found in the general population. [6]
Moreover, one-sixth of all PLWHA in the U.S. pass through the
CJS annually, [6] making these settings important sites for
detection and treatment of HIV infection. [7] Though PLWHA
in prisons achieve high rates of viral suppression [8] while
incarcerated and have recently achieved similar mortality as non-
prisoners, [9] the transition to the community is associated with
high post-release mortality [10] and poor HIV treatment
outcomes. [8,11,12].
Reasons for poor post-release outcomes among PLWHA are
complex and multifactoral, [5] but relapse to alcohol and drug use
is common and both are associated with poor HIV treatment
persistence and adherence. [13,14,15,16,17] Pre-incarceration
opioid dependence is common, especially among those with
HIV infection. [18,19,20] The chronic, relapsing nature of opioid
dependence results in 85% to 90% of such persons relapsing to
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incarceration. [21].
Despite evidence to support successful treatment for opioid
dependence using opioid substitution treatment (OST) in com-
munity and CJS settings, (e.g. methadone and buprenorphine),
[22,23,24,25] OST is seldom available for treatment within the
CJS or upon release in the U.S. [26,27] Cited reasons for the lack
of implementation of OST involving CJS populations are multiple,
including: 1) ideology that OST is replacing one addiction for
another; 2) stringent licensing regulations; 3) concerns about
diversion; and 4) costs. [28,29,30] In a recently published pilot
study of 23 HIV-infected released prisoners with pre-incarceration
criteria for opioid dependence, we confirmed that buprenorphine/
naloxone (BPN/NLX) treatment was feasible in the vulnerable 12-
week post-release period and was highly acceptable and highly
associated with short-term viral suppression. [31] We now extend
these findings to a larger sample for a longer duration, and explore
the impact of BPN/NLX treatment on HIV treatment outcomes
compared to similar patients who did not receive BPN/NLX.
Methods
The rationale and description of the overall prospective study of
directly administered antiretroviral therapy (DAART) has been
describe [32,33] as have the procedures for BPN/NLX induction.
[31].
Recruitment
Eligible subjects were recruited during the years 2005–2010
from among 154 HIV-infected prisoners transitioning to the
community enrolled in a randomized controlled trial (RCT) of
directly administered antiretroviral therapy (DAART). [32,33],
Subjects enrolled in this RCT who met pre-incarceration DSM-IV
criteria for opioid-dependence, were assessed for interest in opioid
substitution therapy (OST) with either methadone or BPN/NLX.
Additional eligibility criteria included: 1) returning to either New
Haven or Hartford; 2) age $18 years; 3) a negative urine
pregnancy test for women and willingness to use contraception;
and 4) expressing an interest in MAT. As part of the ongoing
parent RCT, subjects were randomized 2:1 to receive DAART
versus self-administered therapy (SAT). [32].
Study Procedures
Within 90 days before community-release, all subjects under-
went informed consent, baseline assessments and chart review.
Assessments included demographic information, mental illness and
chemical dependence screening using the Mini-International
Neuropsychiatric Interview (M.I.N.I), [34] Addiction Severity
Index (ASI), [35,36] and Alcohol Use Disorders Identification Test
(AUDIT) [37] and urine toxicology screening. Alcohol and drug
use questions referred to the pre-incarceration period to establish
historical diagnoses, as no subject was actively using drugs or
alcohol while incarcerated based on urine testing. Subjects
underwent secondary consent procedures after release to avoid
any perceived or real coercion. A more detailed study protocol and
baseline characteristics from the parent study have been a recently
published. [33] Additional post-release activities included baseline
physical exam and weekly assessment of opioid craving (10-point
Likert scale), buprenorphine satisfaction (10-point Likert scale),
weekly urine toxicology screening using the NIDA-6 (opioids,
cocaine, methadone, benzodiazepines, marijuana, methamphet-
amines) and separate urine tests for oxycodone and buprenorphine
(Redwood Biotech, Santa Rosa, CA). Baseline and quarterly HIV-
1 RNA levels (Amplicor 1.5; Roche) and CD4 lymphocyte counts
(FACS; Quest) were obtained.
Ethics
The Yale University Human Investigation Committee and the
Connecticut Department of Correction Research Advisory Com-
mittee approved this study and the parent study is registered at
www.clinicaltrials.gov (NCT00786396). Additional assurances to
protect the participants were obtained from the Office of Human
Research Protection (OHRP) at the Department of Health and
Human Services, and a Certificate of Confidentiality from the
National Institutes of Health was also obtained. As mentioned
above, written consent to participate in the parent trial [33] and
this sub-study was obtained from the participants prior to
enrollment. If the subject did not want to participate in this sub-
study, they were allowed to continue in the parent study. If also at
any time they wished to stop the study, they were told they could
do so and would be referred to a community substance use
treatment program if they wished to continue to receive relapse
prevention treatment for opioid dependence.
Buprenorphine Induction Process
BPN/NLX induction and maintenance procedures have been
described previously, [31] and others have more recently
described BPN implementation issues in criminal justice settings
for patients not infected with HIV. [38] Briefly, BPN/NLX
induction was allowed up to 30 days post-release from prison;
however, the day of release was targeted when possible. Baseline
urine toxicology testing for subjects inducted on the day of release
confirmed that there was no relapse that occurred on the day of
release or in the immediate 72 hours during incarceration. Due to
low expected tolerance at the time of prison-release, subjects were
initially administered 2.0 mg/0.5 mg BPN/NLX and increased by
2 mg/0.5 mg increments of BPN/NLX daily, as tolerated, to
reduce the craving score to 1, while avoiding opioid agonist side
effects. BPN/NLX dose, craving for opioids, opioid withdrawal
symptoms, opioid-agonist side effects, and urine toxicology
screening were collected daily during the induction and weekly
thereafter.
Buprenorphine Maintenance Therapy (BMT) Procedures
BMT was defined as having received even a single dose of
BPN/NLX along with weekly, standardized and manual-based
counseling per protocol [39] for 45–60 minutes by a certified
substance abuse treatment counselor for the first 12 weeks;
frequency of counseling thereafter varied based on clinical
response and provider preference. Counseling is considered
standard care for patients receiving BPN/NLX. Study personnel
linked counseling visits to collection of urine screens and
distribution of weekly refill vouchers. The voucher was not
contingent on urine specimen results. For those randomized to
DAART, BPN/NLX was observed daily along with their cART
and other chronically prescribed medications. For those in the
SAT arm, a 7-day prescription BPN/NLX voucher was provided
to allow the pharmacy to provide the BPN/NLX after providing a
urine specimen and attending the weekly counseling sessions for
the first 12 weeks of the study.
Follow-up
Subjects receiving BMT were evaluated daily by the study
clinician during the induction phase and at least monthly
thereafter. Counselors met with subjects weekly, irrespective of
study assignment, and assessed urine toxicology screening, opioid
Buprenorphine, HIV and Released Prisoners
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tured interviews and phlebotomy for CD4 lymphocyte count and
HIV-1 RNA level were conducted at weeks 4,12 and 24 after
release.
Analytic Strategy
All statistical analyses were conducted using STATA v.10
(StataCorp LP, Texas, USA). Outcomes from the first 24 weeks
are reported for all 94 subjects meeting DSM-IV criteria for opioid
dependence who were including in the parent RCT. The primary
outcome was defined as the proportion of patients achieving
maximal virological suppression (MVS), or HIV-1 RNA ,50 cop-
ies/mL, at 24 weeks. Using logistic regression analyses, univariate
analysis was performed to assess the impact of potential
independent variables associated with the primary outcome.
Subsequently, a multivariate model was fitted to the data, using
both backward and forward stepwise regression approaches
incorporating Bonferroni correction; P-values censored at #0.20
were restricted to enter and leave the model. Aikake (AIC) and
Bayesian Information Criterion were applied to each model to
assess goodness of fit and to avoid over fitting of data. Missing
HIV-1 RNA values were considered as failures (HIV-1 RNA
.50 copies/mL).
Among the 94 participants who met pre-incarceration DSM-IV
criteria for opioid dependence, we sought to conduct a naturalistic
study comparing those who initiated buprenorphine maintenance
treatment (BMT) with those who did not. Those not initiating
BMT included those that selected either methadone maintenance
therapy (MMT; N=9) or no OST (N=35). Because of the
naturalistic nature of the follow-up, those not receiving BMT
received what is routinely available as standard of care in
community settings for those receiving MMT and no OST
(including available counseling).
The independent substance abuse variables of interest were: 24-
week retention in BPN/NLX treatment and degree of addiction
severity using the Addiction Severity Index (ASI). [35] Urine
toxicology results were not collected for the non-BPN/NLX
group, therefore they were not included in the univariate or
multivariate analysis nor was this group compared to the BMT
group. Urine toxicology results were available for the BPN/NLX
group only and were measured as the percentage of opioid-free
and cocaine-free urine toxicology results over 24 weeks. Missing
urine results were adjudicated in the following sequential manner:
1) self-report at weekly visits; and 2) last value carried forward only
if a single missing value was noted; 3) for subjects who remained in
the trial, missing consecutive urine values were considered positive.
Therefore, the proportion of positive urine tests for the BPN/NLX
group was calculated as the percent positive out of the number
who remained in the trial for each week and included missing
value adjudication. Craving and satisfaction scores for the BPN/
NLX group only were calculated as the mean for those individuals
whose results were reported weekly.
Results
Figure 1 depicts the disposition of the 154 subjects who were
included in the parent trial: 94 (61%) met pre-incarceration DSM-
IV criteria for opioid dependence and about half (N=50, 53%)
opted to receive BPN/NLX (i.e, BPN group). Among the 44 (47%)
who chose not to receive BPN/NLX (i.e. Non-BPN group), 9
(20.5%) selected methadone and 79.5% preferred no MAT. The
availability of follow-up data for the primary outcomes (HIV-1
RNA levels) at 24 weeks was significantly higher in the BPN group
than in the non-BPN group (98% vs. 84.8%, p=0.024).
Table 1 compares the baseline characteristics of the two groups
(BPN vs Non-BPN). In general, the two groups were similar with
regard to age and gender, self-reporting anticipated homelessness
at the time of release, and meeting DSM-IV criteria for a major
Axis I disorder. Similarly, baseline opioid craving did not differ
nor did the levels of addiction severity, cocaine use, depressive
symptoms, type of cART regimen prescribed, baseline viral load,
CD4 characteristics or proportion that had previously received
methadone treatment. The groups were different, however, on two
important characteristics; race/ethnicity and city of residence.
Hispanics, compared to whites and blacks, were more likely to
comprise the BPN group and Hartford site groups.
Table 2 provides the contribution of various potentially
independent effects on the primary outcome, achieving maximal
viral suppression (MVS) at 24 weeks. The factors that were found
to be statistically significantly associated with achieving MVS at
24 weeks in the univariate analysis were: retention on BPN/NLX
for 24 weeks (p=0.030); male gender (p=0.047); and having a
baseline HIV -1 RNA level of ,50 copies/ ML (p,0.001). After
inclusion of these covariates in the multivariate regression analysis
model separately, retention on BPN/NLX treatment for 24 weeks
Figure 1 Subject Disposition. Difference of data follow-up between
Buprenorphine/Naloxone and Non-Buprenorphine retention is statisti-
cally significant, p=0.024.
doi:10.1371/journal.pone.0038335.g001
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BPN/NLX
(N=50)
No BPN/NLX
(N=44)
Total Sample
Population (N=94) P value
Gender 0.10
Male 44 (88.0%) 33 (75.0%) 77 (81.9%)
Female 6 (12.0%) 11 (25.0%) 17 (18.9%)
Mean Age (years), S.D. 45.6266.05 46.5967.52 46.0766.76 0.27
Ethnicity 0.00
White 6 (12.0%) 11 (25.0 %) 17 (18.9%)
Black 16 (32.0%) 24 (54.6%) 40 (42.6%)
Hispanic 28 (56.0%) 9 (20.4%) 37 (39.4%)
Study Site 0.01
New Haven 13 (26.0%) 23 (52.3%) 36 (38.3%)
Hartford 37 (74.0%) 21 (47.7%) 58 (61.7%)
Homelessness 19 (43.2%) 14 (38.9%) 33 (41.3%) 0.70
Median months of Incarceration 8 7 7.5 0.81
Study arm assignment 0.39
SAT 14 (28.0%) 16 (36.4%) 30 (31.9%)
DAART 36 (72.0%) 28 (63.6%) 64 (68.1%)
Axis I psychiatric diagnoses (DSM-IV) 26 (52.0%) 17 (38.6%) 43 (45.7%) 0.20
Mood disorders 22 (44.0%) 11 (25.0%) 33 (35.1%) 0.05
Anxiety disorders 16 (32.0%) 12 (27.3%) 28 (29.8%) 0.62
Psychotic disorders 7 (14.0%) 6 (13.6%) 13 (13.8%) 0.96
Hazardous Drinking (AUDIT§8) 13 (26.0%) 15 (34.1%) 28 (29.8%) 0.39
Opioid Craving (§5) 27 (56.3%) 3 (60.0%) 30 (56.6%) 0.88
Addiction Severity (ASI)
Alcohol 0.2960.12 0.2760.15 0.28060.137 0.70
Drugs 0.1060.18 0.2760.17 0.13160.187 0.63
Lifetime Cocaine use 48 (96.0%) 41 (93.2%) 89 (94.7%) 0.54
Mean CES-D score 18.3669.85 18.38612.32 18.37611.02 0.70
Major depression using CES-D
(score ¼ > 16)
29 (61.7%) 20 (47.6%) 49 (55.1%) 0.18
Mean QIDS score 8.2964.65 8.4465.77 8.3665.18 0.48
Opioid Dependence Score (ODS) 6.2461.71 6.1461.58 6.1961.64 0.86
Social Support Scale 61.49624.81 66.67622.26 63.91623.67 0.75
Trust in Physician 66.8666.93 68.2066.93 67.4966.92 0.68
Health-related quality of life (SF-36)
Physical Composite Score 46.74612.38 43.10613.60 45.04613.02 -
Mental health composite score 43.15613.81 44.97614.03 44.00613.87 -
Physical function score 74.18634.44 70.47632.33 72.45633.34 0.35
Role-physical score 67.35643.96 56.98646.07 62.50645.01 0.55
Bodily pain score 65.66635.94 62.03637.92 63.97636.72 0.66
General health score 54.18625.15 51.40627.70 52.88626.26 0.02
Vitality score 61.12623.61 51.05626.49 56.41625.37 0.43
Social functioning score 68.11630.94 66.86632.15 67.53631.34 0.35
Role-emotional score 52.38645.64 66.67643.64 59.06645.05 0.12
Mental health score 66.04622.67 62.70623.04 64.48622.78 0.44
Had Methadone prior to incarceration 37 (75.5%) 26 (59.1%) 63 (67.7%) 0.09
Dosing schedule 0.63
Once daily 41 (82.0%) 36 (85.7%) 77 (83.7%)
Twice daily 9 (18.0%) 6 (14.3%) 15 (16.3%)
Baseline antiretroviral therapy regimens 0.07
NNRTI+NRTIs 23 (46.0%) 12 (28.6%) 35 (38.0%)
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baseline HIV-1 RNA ,50 copies/ mL were found to significantly
associated with achieving MVS at the end of the 24 weeks among
the OD subjects (n=94), while black race was negatively
associated with this primary outcome. The DAART intervention
and ‘receiving any buprenorphine or methadone’ were not found
to be statistically significantly associated with MVS.
Figure 2 shows the percentage of the 50 subjects who were
retained on BPN/NLX over the 24 weeks. Forty-two (84%) of
these completed the 3-day induction process and nearly half (48%)
were retained on BPN/NLX for the entire 24 weeks. As indicated
in the figure at the 12-week mark when the mandatory 12-week
counseling was completed, there was a significant loss in retention.
Reasons for discontinuation of BPN/NLX included reincarcera-
tion, hospitalization for issues not related to BPN/NLX, request
for opioid pain medications, and in one case, a change to
methadone.
Table 3 depicts the results of the HIV treatment outcomes at
baseline compared to 6 months between three naturalistic
observation groups: the Non-BPN group (n=44), the BPN group not
retained for 24 weeks (n=33) and the BPN group of subjects who were
retained for the full 24 weeks (n=17). There was no statistically
significant difference for mean CD4 count over the 6 months
between the three groups (p=0.38) nor was there for the
percentage having a VL ,400 copies/mL (p=0.08). There was,
however, a statistically significantly greater percentage of the BPN
group who were retained for 24 weeks group having MVS over the
6 months when compared to the Non-BPN and the BPN and not
Retained for 24 Weeks group (p=0.01).
Figure 3 depicts the urine toxicology results that were available
for the 50 subjects who began induction with BPN/NLX over the
24 weeks. Eighteen percent had urine toxicology tests positive for
opioids at the time of the first day of induction (mean time after
release was approximately 7 days), and 20% had urine opioid
toxicology tests positive at the end of 24 weeks. Twenty-two
percent had urine toxicology tests positive for cocaine at time of
induction, and 30% had cocaine positive urine toxicology tests at
end of 24 weeks. Only the subjects who were in the BPN-group
had weekly urine toxicology results, therefore comparisons with
regard to opioid and cocaine use cannot be made between the
group that selected BPN and the group that did not.
Figure 4 depicts the mean opioid craving and satisfaction
scores for those receiving BMT over the 24 weeks for the 50 BPN/
NLX subjects. The mean opioid craving score was 5.5 at time of
baseline induction. This score was reduced to a mean craving
score of 1.0 by the end of week 1, and remained consistently there
by the 24-week end point. Similarly, satisfaction with BPN/NLX
treatment was high with a mean satisfaction score of 9 by the end
of the first week of induction rising to a mean of 10 throughout the
rest of the 24 weeks of the study.
Discussion
To our knowledge, this is the largest longitudinal follow-up of
HIV-infected prisoners on antiretroviral therapy and meeting pre-
incarceration DSM-IV criteria for opioid dependence. The
findings from this study have several important implications as
described below.
First, being retained on BPN/NLX, along with standardized
counseling recommended for HIV-infected patients on BMT, was
superior in sustaining maximal viral suppression compared to
those not receiving BPN/NLX. This remained true in this
naturalistic study where participants could choose their own
post-release treatment options, even when controlling for receipt of
other OST, including methadone. Unlike our previous pilot BPN/
NLX study, we not only examined participants for a longer
treatment duration (24 weeks), but also were able to compare
outcomes to other opioid dependent participants who did not
receive BPN/NLX, including those opting for methadone.
Second, the finding that retention on BMT, along with related
counseling and follow-up, was strongly and significantly correlated
with MVS confirms findings from other studies where integrating
BPN/NLX into HIV clinical care settings is independently
associated with viral suppression. [31,40] [41] Compared to these
community-derived samples, this study’s subject population had
more psychiatric, social and medical co-morbidity, and despite
this, retention on BMT was similar. [32] The subjects in this study
were highly representative of the criminal justice system with 41%
being homeless upon release; 45% having an Axis I DSM-IV
Table 1. Cont.
BPN/NLX
(N=50)
No BPN/NLX
(N=44)
Total Sample
Population (N=94) P value
Boosted PI+NRTIs 22 (44.0%) 22 (52.4%) 44 (47.8%)
Non-boosted PI+NRTIs 5 (10.0%) 4 (9.5%) 9 (9.8%)
Others 0 4 (9.5%) 4 (4.4%)
Viral Load N=50 N=43 N=93 0.79
HIV-1 RNA,400 copies/mL 36 (72.0%) 32 (74.4%) 68 (73.1%)
HIV-1 RNA$400 copies/mL 14 (28.0%) 11 (25.6%) 25 (26.9%)
Viral Load N=50 N=43 N=93 0.38
HIV-1 RNA,50 copies/mL 29 (58.0%) 21 (48.8%) 50 (53.8 %)
HIV-1 RNA$50 copies/mL 21 (42.0%) 22 (51.2%) 43 (46.2 %)
Log HIV-1 RNA
(among VL.50 copies/mL)
2.4161.11 2.3461.04 2.3761.07 0.59
CD4+ lymphocytes (cells/mL) 375.46190.9 362.06261.6 369.16225.6 0.21
Legend: SAT=Self-administered therapy; DAART=directly administered antiretroviral therapy; ASI=Addiction Severity Index; CES-D=Clinical Epidemiological Survey
Depression; QIDS=Quick Inventory Depression Survey; ODS=Opioid dependency Scale; SF=SF-36 QoL=Quality of Life scale; NNRTI=non-nucleoside reverse
transcriptase inhibitors; NRTI=nucleoside reverse transcriptase inhibitors; PI=protease inhibitors; VL=viral load.
doi:10.1371/journal.pone.0038335.t001
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on the AUDIT; and 18% having lifetime history of cocaine abuse
prior to incarceration. An intervention that can succeed in
suppressing HIV viral load in released prisoners who have
significant psychosocial comorbidity is highly important. [5] This
is particularly salient since most released HIV-infected prisoners
Table 2. Correlates of factors associated with maximum viral suppression (HIV-1 RNA,50 copies/ml) among opioid dependent
clients at 24 weeks (N=94).
Univariate Analysis Multivariate Model
OR (95%CI) p value AOR (95%CI) p value
Received any BPN 1.25 (0.55–2.84) 0.59
Received any BPN or methadone 1.36 (0.59–3.15) 0.47
Retained on BPN for 24weeks 4.32 (1.15–16.2) 0.03* 5.37 (1.15–25.1) 0.03*
Lifetime Cocaine use 0.32 (0.03–2.98) 0.32
Study Arm
SAT referent
DAART 1.56 (0.65–3.74) 0.32
Gender
Female referent
Male 3.03 (1.01–9.08) 0.05* 4.23 (1.00–18.0) 0.05
Age 1.00 (0.94–1.06) 0.99
Race/Ethnicity
White referent
Black 0.38 (0.11–1.27) 0.12 0.13 (0.03–0.68) 0.02*
Hispanic 0.68 (0.20–2.36) 0.55 0.29 (0.06–1.40) 0.12
Months of incarceration 1.02 (0.99–1.05) 0.18 1.02 (0.99–1.05) 0.14
Homeless 1.09 (0.43–2.73) 0.87
Study Site
Hartford referent
New Haven 0.78 (0.34–1.83) 0.58
DSM-IV psychiatric axis I diagnoses 0.88 (0.39–2.01) 0.77
Mood 0.83 (0.35–1.96) 0.68
Anxiety 0.98 (0.40–2.40) 0.78
Psychotic 1.22 (0.37–4.04) 0.75
Hazardous Drinking 0.80 (0.33–1.95) 0.62
ASI- Alcohol 0.52 (0.03–10.22) 0.66
ASI- Drug 0.35 (0.04–3.15) 0.35
Mean Craving Score ($5) 0.88 (0.29–2.62) 0.82
Depression (CES-D$16) 0.80 (0.34–1.88) 0.61
Depression (QIDS.11) 0.61 (0.25–1.46) 0.27
Social Support Scale 0.99 (0.97–1.01) 0.39
Trust in Physician 1.03 (0.97–1.09) 0.36
Quality of Life – Physical Composite Score 1.00 (0.97–1.04) 0.77
Quality of Life – Mental Composite Score 1.00 (0.97–1.03) 0.99
Dosing schedule )
Once daily referent
Twice daily 1.50 (0.47–4.81 0.50
Baseline HIV-1 RNA,50 (copies/mL) 5.91 (2.40–14.6) ,0.001* 10.5 (3.21–34.1) ,0.001*
AIC 101.1058
BIC 118.5263
*binomial variables=0 is the referent group.
Legend: OR=odds ratio, AOR=adjusted odds ratio; BPN=Buprenorphine; CI=confidence interval; ASI=Addiction Severity Index; Craving=craving for opioids Likert
scale 1–10 Dosing Schedule=dosing of cART; SAT=Self-administered Therapy; DAART=Directly Administered Antiretroviral Therapy; QIDS=Quick Inventory
Depression Scale; CES-D=Center for Epidemiologic Studies on Depression scale.
doi:10.1371/journal.pone.0038335.t002
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absence of other prevention activities (e.g. condom use, risk
reduction counseling), cART is an effective approach to reduce
HIV transmission. [43].
Third, though the DAART intervention was superior to SAT in
the parent trial, it was not independently associated with MVS
among these opioid dependent subjects. [32] The multivariate
analysis among opioid dependent participants, however, revealed
that being retained on BMT, irrespective of DAART randomi-
zation, was the mediating factor in sustaining maximal viral
suppression. Shorter retention on BPN/NLX and receipt of
methadone was not correlated with MVS. This suggests that
optimizing the use of OST using BPN/NLX among opioid
dependent HIV-infected prisoners, especially with optimal reten-
tion on substance abuse treatment, could improve HIV treatment
outcomes when released to the community. Although DAART is
an effective intervention, OST using BPN/NLX is less costly and
should be considered as a potential post-release mechanism to
improve HIV treatment outcomes among opioid dependent
released prisoners. The extent that the use of other forms of
medication-assisted therapy or in treating other substance use
disorders including alcohol remains to be determined. [5,44].
Fourth, craving for opioids is associated with a high rate of
opioid relapse among those who have undergone supervised
opioid withdrawal. [45] Craving remained high at the time of
release in this study, especially for a group who had been
incarcerated for many months and after forced abstinence from
opioids. Indeed, 20% had already relapsed to opioid use within
Figure 2 Proportion of Clients on Buprenorphine/Naloxone Over Time. 0: induction; **: N: number of clients receiving buprenorphine.
doi:10.1371/journal.pone.0038335.g002
Table 3. HIV treatment outcomes for Buprenorphine group and Non-Buprenorphine group over 24 weeks.
Outcomes Time
Non-BPN
(N=44)
BPN But Not
Retained 24 Weeks
(N=33 )
BPN And
Retained 24 Weeks
(N=17 )
Total Sample
Population
(N=94)
P value of
difference
among 3
groups
Mean CD46 SD
(cells/mL)
Baseline 370.56 262.3 384.66 187.6 360.16 200.2 373.66 225.6
Week 12 492.16 386.1 356.16 237.7 395.36 241.9 425.26 316.8 0.38
Week 24 430.26 287.7 336.96 160.3 382.26 218.6 388.76 238.9
HIV-1 RNA,50 copies/
ml, N (%)
Baseline 21 (48.8%) 19 (57.6%) 10 (58.8%) 50 (53.8%)
Week 12 20 (45.5%) 14 (42.4%) 13 (76.5%) 47 (50.0%) 0.01
Week 24 24 (54.6%) 16 (48.5%) 14 (82.4%) 54 (57.5%)
HIV-1 RNA,400 copies/
ml, N (%)
Baseline 32 (74.4%) 23 (69.7%) 13 (76.5%) 68 (73.1%)
Week 12 28 (63.6%) 19 (57.6%) 14 (82.4%) 61 (64.9%) 0.08
Week 24 31 (70.5%) 22 (66.7%) 15 (88.2%) 68 (72.3%)
doi:10.1371/journal.pone.0038335.t003
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relapse to opioid use for some of these subjects, BPN/NLX was
successfully started and linked with cART. This highly feasible,
acceptable and effective intervention likely assisted in their ability
to control the chaos after release by decreasing craving for opioids
and allowing them to be adherent to their cART, thereby
improving the likelihood of effectively suppressing HIV replica-
tion. It is possible that the craving for, and use of cocaine
throughout the study may have contributed to poorer treatment
outcomes by modifying the effect of BPN/NLX as noted in other
studies. [46] Unfortunately urine drug screening was not available
for all participants and the effect of continued cocaine use could
not be evaluated in the multiple regression analysis.
Integrating BPN/NLX with cART for released OD prisoners
has significant public health implications. Suppression of HIV
replication will ultimately contribute to decreases in transmission
of HIV to the uninfected public. ART alone has been found to
reduce spread of HIV infection to serodiscordant couples [4] and
among general populations studies in San Francisco [47],
Vancouver [48], and in Taiwan [49]. In this study, 53% of the
total 94 subjects had MVS at the time of release; and for the BPN
group 60% still had MVS at 6 months after release, a truly
remarkable feature for a group that tends to lose this benefit within
12 weeks after release. [8], [50] This OST intervention study
suggests that treatment using BPN/NLX for opioid dependence
among HIV-infected opioid dependent CJS populations who are
prescribed cART independently enhances viral suppression,
suggesting that BPN/NLX is a crucial component of ‘enhanced
treatment as prevention’. The extent to which CJS administrators,
public health officials and public policy makers adopt BPN/NLX,
or any effective MAT for that matter, remains problematic in that
such evidence-based interventions are generally not available to
CJS populations in the U.S. [30,51] While these data confirm the
benefits of BPN/NLX, future studies should also include
evaluating the effect of methadone and extended-release naltrex-
one on HIV treatment outcomes – the latter being a more recently
approved medication for the treatment of alcohol use disorders
[15,17] and opioid dependence. [52] Extended-release naltrexone
has the potential for less adherence concerns due to its once
monthly injection dosing, as well as having no overdose or
diversion concerns due to its opioid antagonist properties
compared to the opioid agonist medications.
International guidelines have recently been published that
support the use of methadone in HIV-infected patients receiving
cART, DAART for released prisoners and the integration of
DAART into methadone treatment in community settings. [53]
This study provides additional empiric data for the use of BPN/
NLX for HIV-infected opioid dependent prisoners transitioning to
the community as a means to maximize viral suppression, even in
the absence of DAART. The lack of a RCT design and the small
sample size does, however, limit the strength of this recommen-
dation.
There are limitations to this study including the relatively small
sample size and single study site. Receipt of BPN/NLX was not
randomized, therefore potentially introducing selection bias. For
example, those selecting BMT may have been more motivated to
Figure 3 Urine toxicology test results (percent of positive results) among tested clients prescribed buprenorphine/naloxone
(N=50).
doi:10.1371/journal.pone.0038335.g003
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increased motivation may have influenced adherence to BMT
compared to those not selecting BMT. It is clear, however, that
this analytic approach represents a real-world sample and reflects
the realities of what individuals seek as treatment options.
Moreover, it is clear that those selecting BPN/NLX were not
just selecting it over methadone because it might provide more
freedom in their day to day life, since two thirds of BPN/NLX
participants received their BMT daily as observed therapy by
virtue of being in the DAART arm. Though future studies should
consider deploying a randomized controlled trial (RCT) design to
eliminate the possibility of such selection bias, such an approach
will not overcome concerns about inclusion of patient preferences
since it is unlikely that such a RCT could ever realistically be
conducted as placebo-controlled. Additionally, though we know
the extent of the counseling provided to the BMT group, the Non-
BPN comparison group was not followed as closely and did not
include urine toxicology testing. Though counseling has been
demonstrated to enhance the benefits of OST, counseling alone
would be entirely insufficient to provide significant benefit. [54]
Last, there may have been some contributors to retention that
were not measured in this study, such as homelessness, mental
illness status, social support and motivation. It is unlikely that
homelessness contributed differently to outcomes since the two
groups did not differ at baseline, nor did their levels of underlying
depression or addiction severity. The extent to which these factors
contributed to MVS and retention on BPN among the group that
retained and not retained on BPN/NLX for the entire 24 weeks is
unknown. Despite these limitations, this study not only supports
that HIV-infected prisoners transitioning to the community are
more likely to accept BPN/NLX treatment to prevent relapse to
opioid use than methadone maintenance or even no OST at all,
but that retention on BPN/NLX was highly correlated with MVS.
This is particularly salient since most had prolonged periods of
forced abstinence (mean length of time of 7.5 months) and 63%
had been previously treated with methadone maintenance and
none had any knowledge about or experience with BPN/NLX
upon being screened for this study.
In conclusion, buprenorphine induction upon release for HIV-
infected opioid dependent prisoners is highly acceptable and
feasible. Retention on buprenorphine, irrespective of other
medical or psychiatric comorbidity, evidence-based adherence
interventions or use of methadone, was strongly associated with
maximal viral suppression. Buprenorphine maintenance treat-
ment, along with concomitant counseling, effectively enhances the
benefit of cART as enhanced treatment as prevention for released
HIV-infected opioid dependent prisoners and has great potential
to improve health from an individual and public perspective.
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